Plasma heparanase as a significant marker of treatment response in children with hodgkin lymphoma: Pilot study

Pediatric Hematology and Oncology

Volumn 26, Issue 4, 2009, Pages 157-164

  Arush, Myriam Weyl Ben ^a,b   Shafat, I ^b,c   Barak, Ayelet Ben ^a   Shalom, Rachel Bar ^d   Vlodavsky, Eugene ^b,c   Ilan, Neta ^b,c  

^a MEYER CHILDREN S HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Cancer and Vascular Biology Research Center   (Israel)

^d Meyer Children's Hospital ^*  (Israel)

Author keywords

Children; ELISA; Heparanase; Hodgkin lymphoma; Prognostic factor

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; HEPARANASE; METHOTREXATE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PREDNISONE; PROCARBAZINE; TUMOR MARKER; VASCULOTROPIN; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; PILOT STUDY; PLASMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REMISSION; TREATMENT RESPONSE; BLOOD; PRESCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCURONIDASE; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; PILOT PROJECTS; TUMOR MARKERS, BIOLOGICAL;

EID: 67651174460     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010902754917     Document Type: Article

References (22)

1. Pizzo and Poplack. Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: Lippincott; 2006.
2. FolkmanJ.Angiogenesisincancer, vascular, rheumatoid and other diseases.Natl Med. 1995;1:27-31.
3. Pavlakovic H, Von Schutz V, Rossler J, et al. Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer. 2001;92:756-760.
4. Tabone MD, Landman-Parker J, Arcil B. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with solid malignant tumors? Clin Cancer Res. 2001;7:538-543.
5. Ben Arush M, Schenzer P, Maurice S, et al. Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies. Pediatr Hematol Oncol. 2005;22:513-524.
6. Ben Arush M, Ben Barak A, Maurice S, et al. Serum VEGF as a significant marker of treatment response in Hodgkin lymphoma. Pediatr Hematol Oncol. 2007;24:111-115.
7. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cellmatrix interactions. Trends Biochem Sci. 2000;25:349-351.
8. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001;108:341-347.
9. Katz A, Van-Dijk DJ, Aingorn H, et al. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J. 2002;4:996-1002.
10. Shafat I, Zcharia E, Nisman B, et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun. 2006;341:958-963.
11. Nardella C, Steinkuhler C. Radiolabeled heparan sulfate immobilized on microplate as substrate| for the detection of heparanase activity. Anal Biochem. 2004;232:368-375.
12. Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol. 2002;20:3081-3087.
13. Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol. 2002;13(Suppl 1):107-111.
14. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348: 2386-2395.
15. Vlodavsky I, Schirrmacher V, Ariav Y, Fuks Z. Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res. 1983;43: 2704-2711.
16. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006;38:2018-2039.
17. VlodavskyI,Abboud JarrousG, Elkin M.The impactofheparanase and heparinon cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb. 2006;35:116-127.
18. Vlodavsky I, Ilan N, Naggi A. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 2007;13:2057-2073.
19. Mainou-Fowler T, Angus B, Miller S, et al. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma. 2006:47:223-230.
20. Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677-683.
21. Foss HD, Araujo I, Demel G, et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol. 1997;183:44-50.
22. Agarwal B, Naresh KN. Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol. 2003;201:334-335.